CD274 and neoplasm: For example, cetuximab’s ADCC activity can stimulate IFN-y secretion from NK cells, improving NK and DC cross-talk, but it also induces PD-L1 expression and therefore inhibits active T and NK cells and assists in tumor immune escape [93,94].